FDA Combination Products Office Finalizing Manufacturing, Adverse Event Rules
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Office of Combination Products is also developing guidance on how to determine whether a medical product is a device, drug or biologic.
You may also be interested in...
FDA’s Combo Product GMP Reg Speeds Ahead Unchanged
Agency decides to keep the proposed rule, issued in 2009, “largely identical” and denies requests to delay implementation a year.
FDA’s Combo Product GMP Reg Speeds Ahead Unchanged
Agency decides to keep the proposed rule, issued in 2009, “largely identical” and denies requests to delay implementation a year.
Drug Shortage Rules Surface In Latest FDA Regulatory Agenda
FDA has yet to prognosticate on a schedule for other FDASIA-mandated regulations; HHS says that FDA’s priorities for the coming year will involve devices and food, as well as promoting international regulatory cooperation.